Drug Profile
Research programme: utrophin modulators - Summit / University of Oxford
Alternative Names: SMT 022357Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator University of Oxford
- Developer Summit Therapeutics; University of Oxford
- Class Small molecules
- Mechanism of Action Utrophin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Duchenne muscular dystrophy
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in United Kingdom (PO)
- 04 Oct 2016 Summit Therapeutics and Sarepta Therapeutics agree to co-develop utrophin modulators in Turkey, Common Wealth of Independent States and Europe for Duchenne muscular dystrophy
- 17 Nov 2015 Summit Therapeutics extends its collaboration with University of Oxford for development of utrophin modulators for Duchenne muscular dystrophy